Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Agios, Avanmzanite Sign Agreement For Pan-European Partnership For PYRUKYND Launch

Author: Benzinga Newsdesk | June 09, 2025 07:44am
  • PYRUKYND® (mitapivat) is a first-in-class pyruvate kinase (PK) activator, approved by the European Commission for adults with PK deficiency
  • The agreement includes commercialization and distribution rights for potential future indications
  • Furthered by this partnership with Agios, Avanzanite is setting a new paradigm in biotech commercial and distribution partnerships, and in how orphan medicines reach patients across Europe

Posted In: AGIO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist